OPEN ACCESS Freely available online

Advanced Techniques in Biology & Medicine

Editorial

Role of Placental Protein 13 during Pregnancy

Jiabin Meiri*

Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary

EDITORIAL NOTE

At the time of pregnancy, the immune system in mother is tested by the presence of a semi-allogeneic fetus and needs to keep up with its safeguarding role for the mother. One vital occasion in the formation of the placenta that keeps the fetus physically separated from the mother is the attack of the extravillous cytotrophoblasts into maternal spiral arteries to redesign the wall of these vessels, empowering increased and continuous flow of blood from mother's vascular system to the placenta to support fetal development. This interaction is firmly directed, and not all of the essential players are known at this point. During the most recent years, genetic analysis uncovered the presence of regulatory molecules expressed in the placenta of human primates. The journey for novel biomarkers for early recognizable proof of unusual pregnancies uncovered a novel potential candidate, Placental Protein 13 (PP13). PP13 is an individual from the galectin family, a protein dimer created by the trophoblast and is believed to be engaged with ordinary placentation [1]. The gene encoding PP13 (LGALS13) is confined on chromosome 19 in a gene cluster, adjoined by other galectin genes likewise communicated exclusively by the placenta. PP13 protein is emitted from a beginning phase of pregnancy and can currently be recognized in the bloodstream of pregnant ladies from the fifth week of development. Immunohistochemistry and RNA hybridization studies have highlighted its predominant localization in the placental syncytiotrophoblast layer and blood vessels. Supporting the significance of PP13 immune functions in the placenta, the down-guideline of PP13 in the placenta and maternal blood is related with the improvement of extreme pregnancy complications with a powerful immune component, like preeclampsia [2] and miscarriages. So, PP13 builds the apoptosis of T cells and induces the production of interleukin (IL)- 8 (CXCL8) in these cells. It is fundamental since IL-8 is associated with angiogenesis and is additionally an intense chemoattractant for neutrophils [3].

The role of neutrophils in the placenta is still an issue of discussion since their presence was generally connected with adverse pregnancy results, i.e., preeclampsia [4], gestational diabetes [5], and contaminations. Neutrophils were demonstrated to be associated with the exacerbation of the symptoms while delivering extracellular traps (NET), weakening the blood flow to the fetus, and expanding the level of inflammation by delivering several proteases. Since neutrophils are available in the decidua during the first trimester of pregnancy [6], while decidual NK cells advance neutrophil relocation, endurance, and enactment [7]. Also, T cells within the presence of PP13 start delivering chemoattractants to promote neutrophil extravasation to the decidua. PP13 additionally makes zones of necrosis to trap immune cells and permit trophoblast attack and vessel redesigning. Accordingly, we chose to examine the impact of PP13 on neutrophil science. To be sure, neutrophils were at that point portrayed in the cancer setting to sustain cancer growth, supporting angiogenesis, and restraining T cell activity [8].

The following limitations are:

- We diminished the complexity of a placental framework to a 1 or 2 component system in addition to treatment. This distortion of the placental-framework is valuable to get the immediate impact of PP13 on neutrophils yet doesn't consider the role of other immune players or mesenchymal/endothelial cells in additional forming the aggregate of neutrophils. However, it is very difficult to acquire placental tissue from early healthy pregnancies.
- Human neutrophils from non-pregnant donors were utilized to concentrate on the impact of PP13 since blood flowing neutrophils disengaged from pregnant ladies are as of now exposed to PP13 and different harmone concentration and could currently be changed in their natural reaction. Accordingly, we chose to utilize non-exposed neutrophils [9].
- Pregnancy hormones were thought about just for the apoptosis analysis. Since PP13 didn't impact the usefulness of neutrophils, we didn't seek after the impact of this variable.
- One more basic highlight examine is the concentration of PP13 utilized for the review, this matched the estimation of the focus estimated in human placenta toward the end of the second through to the third trimester [10]. Tragically, no information is accessible on placental PP13 fixations at beginning phases of development.

Correspondence to: Jiabin Meiri, Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary, E-mail: jiabin@med.meiri.edu

Received: 18-Mar-2022, Manuscript No. ATBM-22-16295; **Editor assigned:** 20-Mar-2022, PreQC No. ATBM-22-16295 (PQ); **Reviewed:** 03-Apr-2022, QC No. ATBM-22-16295; **Revised:** 08-Apr-2022, Manuscript No. ATBM-22-16295 (R); **Published:** 15-Apr-2022, DOI: 10.35248/2379-1764.22.10.345.

Citation: Meiri J (2022) Role of Placental Protein 13 during Pregnancy. Adv Tech Biol Med. 10: 345.

- The BeWo cell line is gotten from first trimester choriocarcinoma cells rather than essential trophoblast for the co-culture tests, since essential trophoblast cells are trying to get. We know that this doesn't totally represent trophoblast cells.

CONCLUSION

Overall, we portray the polarizing impact of a placenta-explicit galectin on neutrophils. Since placenta and tumors share common highlights, i.e., obtrusiveness, high levels of cell turnover, necessity for angiogenesis, immune guideline to suppress the versatile immune reaction to allo-/cancer antigens, we recommend that PP13 could move neutrophils toward a placental-development tolerant aggregate, reviewing the one observed in disease while keeping up with all their essential functions and capacities to respond to bacterial overwhelming.

REFERENCES

1. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. (2004) 25:608–22.
2. Muro P, Capobianco G, Lepedda AJ, Nieddu G, Formato M, Tram NHQ, et al. Plasma PP13 and urinary GAGs/PGs as early markers of pre-eclampsia. Arch Gynecol Obstetr. (2016) 294:959–65.
3. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers. (2019) 11:564.
4. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol. (2005) 66:1146–54.
5. Stoikou M, Grimolizzi F, Giaglis S, Schäfer G, van Breda SV, Hoesli IM, et al. Gestational diabetes mellitus is associated with altered neutrophil activity. Front Immunol. (2017) 8:1749.
6. Amsalem H, Kwan M, Hazan A, Zhang J, Jones RL, Whittle W, et al. Identification of a novel neutrophil population: proangiogenic granulocytes in second-trimester human decidua. J Immunol. (2014) 193:3070–9.
7. Croxatto D, Micheletti A, Montaldo E, Orecchia P, Loiacono F, Canegallo F, et al. Group 3 innate lymphoid cells regulate neutrophil migration and function in human decidua. Mucosal Immunol. (2016) 9:1372–83.
8. Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. (2019) 133:2159–67.
9. Than NG, Sumegi B, Than GN, Berente Z, Bohn H. Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. Placenta. (1999) 20:703–10.
10. Than NG, Abdul Rahman O, Magenheim R, Nagy B, Fule T, Hargitai B, et al. Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch. (2008) 453:387–400.